semaglutide aloha oregon SkinnyRx SkinnyRx: Injectable Semaglutide (GLP-1)

Citric Acid

Glucagon-like peptide 1 (GLP-1) based therapies have seen a meteoric rise in popularity (about 300%1 increased use between 2018-2023)

FLOW investigators studied the effects of semaglutide (Ozempic, 1 mg/week) versus placebo in patients with type 2 diabetes and chronic kidney disease (low GFR and urine microalbumin)

With the help of GLP-1 treatments, patients living with obesity and obesity-related conditions can define success on their own terms.

Glucagon-like peptide-1 receptor agonists, originally developed for the treatment of metabolic disorders, have recently emerged as promising candidates for the management of substance use disorders